Adaptive Biotechnologies Corporation Stock price

Equities

ADPT

US00650F1093

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.21 USD +11.07% Intraday chart for Adaptive Biotechnologies Corporation -3.60% -34.49%
Sales 2024 * 176M Sales 2025 * 221M Capitalization 466M
Net income 2024 * -193M Net income 2025 * -154M EV / Sales 2024 * 2.1 x
Net cash position 2024 * 96.2M Net cash position 2025 * 242M EV / Sales 2025 * 1.01 x
P/E ratio 2024 *
-2.44 x
P/E ratio 2025 *
-3.1 x
Employees 709
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.94%
More Fundamentals * Assessed data
Dynamic Chart
JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating MT
Adaptive Biotechnologies' Q4 Loss Widens; Revenue Declines; Shares Down MT
Transcript : Adaptive Biotechnologies Corporation, Q4 2023 Earnings Call, Feb 14, 2024
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q4 Revenue $45.8M, vs. Street Est of $48.5M MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : Adaptive Biotechnologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM
Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting CI
Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Adaptive Biotechnologies Corporation, Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q3 Revenue $37.9M, vs. Street Est of $43M MT
Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023 CI
Adaptive Biotechnologies Partners With BeiGene on Minimal Residual Disease Testing of Potential Treatments for Lymphoid Malignancies MT
Adaptive Biotechnologies Corporation Announces New Translational Collaboration to Measure Minimal Residual Disease with Clonoseq(R) Assay Across Beigene's Lymphoid Malignancy Pipeline CI
Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating MT
BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating MT
More news

Latest transcript on Adaptive Biotechnologies Corporation

1 day+11.07%
1 week-5.03%
Current month-21.90%
1 month-24.82%
3 months-37.18%
6 months-43.09%
Current year-34.49%
More quotes
1 week
2.75
Extreme 2.75
3.34
1 month
2.75
Extreme 2.75
4.33
Current year
2.75
Extreme 2.75
5.07
1 year
2.61
Extreme 2.605
9.08
3 years
2.61
Extreme 2.605
44.97
5 years
2.61
Extreme 2.605
71.25
10 years
2.61
Extreme 2.605
71.25
More quotes
Managers TitleAgeSince
Founder 51 09-09-07
Chief Executive Officer 49 09-09-07
President 52 11-03-31
Members of the board TitleAgeSince
Director/Board Member 61 13-01-31
Director/Board Member 68 13-12-31
Director/Board Member 58 18-02-12
More insiders
Date Price Change Volume
24-03-28 3.21 +11.07% 2,000,065
24-03-27 2.89 +0.35% 3,386,198
24-03-26 2.88 -7.69% 1,918,938
24-03-25 3.12 -3.70% 1,157,058
24-03-22 3.24 -2.70% 1,607,063

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.21 USD
Average target price
6.833 USD
Spread / Average Target
+112.88%
Consensus
  1. Stock
  2. Equities
  3. Stock Adaptive Biotechnologies Corporation - Nasdaq